LeMaitre Vascular (NASDAQ:LMAT) Receives "Outperform" Rating from Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT - Free Report) in a research report report published on Friday, Benzinga reports. Oppenheimer currently has a $93.00 price target on the medical instruments supplier's stock, up from their previous price target of $90.00.

Other equities research analysts have also issued reports about the stock. Barrington Research increased their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday. JMP Securities raised their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 20th. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a "buy" rating and a $105.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective on the stock. Finally, StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, LeMaitre Vascular currently has an average rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Trading Up 7.3 %

Shares of LMAT stock traded up $6.49 during mid-day trading on Friday, reaching $94.88. The stock had a trading volume of 343,615 shares, compared to its average volume of 123,348. LeMaitre Vascular has a 1-year low of $45.96 and a 1-year high of $101.67. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 59.86, a PEG ratio of 2.33 and a beta of 0.88. The business's fifty day moving average is $89.53 and its 200-day moving average is $82.77.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular's revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period last year, the firm posted $0.33 EPS. On average, analysts forecast that LeMaitre Vascular will post 1.86 earnings per share for the current year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently made changes to their positions in LMAT. Summit Global Investments grew its stake in LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock valued at $575,000 after acquiring an additional 146 shares in the last quarter. Shaker Investments LLC OH grew its position in shares of LeMaitre Vascular by 1.3% in the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier's stock valued at $1,138,000 after purchasing an additional 175 shares in the last quarter. NBC Securities Inc. increased its holdings in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after buying an additional 188 shares in the last quarter. Finally, nVerses Capital LLC boosted its stake in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock worth $66,000 after buying an additional 200 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.